There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.
Aki Morikawa MD, PhD
Advertisement
Articles by Aki Morikawa MD, PhD
Advertisement
Latest Updated Articles
- Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer
Published: January 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
3
Career Stage and Location Found to Impact Oncology Coverage in the US
4
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
5
